Quick Answer
PLUS THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $4.26 million for the year ending 2025.
- PLUS THERAPEUTICS, INC. showed an increase of +5,500.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from PLUS THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $38.10 million | Q3 2010: $30.73 million | Q1 2011: $42.65 million | Q2 2011: $33.23 million | Q3 2011: $40.80 million | Q1 2012: $34.40 million | Q2 2012: $25.77 million | Q3 2012: $17.63 million | Q1 2013: $16.40 million | Q2 2013: $13.62 million | Q3 2013: $10.21 million | Q1 2014: $12.80 million | Q2 2014: $12.76 million | Q3 2014: $7.85 million | Q1 2015: $13.20 million | Q2 2015: $23.84 million | Q3 2015: $18.97 million | Q1 2016: $9.36 million | Q2 2016: $20.04 million | Q3 2016: $14.92 million | Q1 2017: $6.26 million | Q2 2017: $9.03 million | Q3 2017: $4.78 million | Q1 2018: $5.90 million | Q2 2018: $3.08 million | Q3 2018: $6.81 million | Q1 2019: $3.87 million | Q2 2019: $4.53 million | Q3 2019: $16.83 million | Q1 2020: $16.06 million | Q2 2020: $9.27 million | Q3 2020: $7.63 million | Q1 2021: $14.45 million | Q2 2021: $17.16 million | Q3 2021: $21.28 million | Q1 2022: $21.24 million | Q2 2022: $18.09 million | Q3 2022: $20.27 million | Q1 2023: $12.72 million | Q2 2023: $10.90 million | Q3 2023: $11.01 million | Q1 2024: $2.90 million | Q2 2024: $4.91 million | Q3 2024: $1.22 million | Q1 2025: $9.87 million | Q2 2025: $2.23 million | Q3 2025: $13.29 million.
- Over the full 18 years of available data (2008 to 2025), PLUS THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has declined by 66.3%.
- Historical annual values: Fiscal year 2025: $4.26 million | Fiscal year 2024: $76.0 thousand | Fiscal year 2023: $8.55 million | Fiscal year 2022: $18.12 million | Fiscal year 2021: $18.40 million | Fiscal year 2020: $8.35 million | Fiscal year 2019: $17.55 million | Fiscal year 2018: $5.26 million | Fiscal year 2017: $9.55 million | Fiscal year 2016: $12.60 million | Fiscal year 2015: $14.34 million | Fiscal year 2014: $14.62 million | Fiscal year 2013: $15.51 million | Fiscal year 2012: $25.72 million | Fiscal year 2011: $36.92 million | Fiscal year 2010: $52.67 million | Fiscal year 2009: $12.85 million | Fiscal year 2008: $12.61 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: